Back to News

Announcing a New Webinar Series on Mineralocorticoid Receptor Antagonists (MRAs) and Diabetic Kidney Disease (DKD) Management

Connect to the first webinar on September 7, 2021, from 3 – 4.15 p. m. CEST

Register here.

Prevention and treatment of DKD are critical to the future of global kidney health. Previously, the use of MRA in DKD has been limited by its adverse side effects. The development of non-steroidal MRAs seeks to optimize DKD treatment without these unfavorable consequences.

This series will highlight new research and developments in this rapidly evolving field and present the outcomes of the FIDELIO and FIGARO trials.

Join us for the first session in the series:


MRAs in CKD: Lessons from a Scientist, an Investigator, and a Trialist

Speakers Paola Fioretto (Italy), Peter Rossing (Denmark), and Mike Walsh
(Canada) will present:

  • DKD Mechanisms and the potential of MRAs
  • Outcomes of the FIDELIO-DKD clinical trial
  • Implications of FIDELIO’s design and sub-group analyses for clinical practice

The webinar will be moderated by Angela Yee-Moon Wang (China) and Masaomi Nangaku (Japan).

Access further reading, submit questions, and register for the webinar here.


Help us advance kidney health worldwide
Join the ISN
Back to News